Id: acc1661
Group: 2sens
Protein: eIF4E
Gene Symbol: EIF4E
Protein Id: P06730
Protein Name: IF4E_HUMAN
PTM: phosphorylation
Site: Ser209
Site Sequence: HADTATKSGSTTKNRFVV---
Disease Category: Cancer
Disease: Glioma
Disease Subtype:
Disease Cellline: U373
Disease Info:
Drug: temozolomide(TMZ)
Drug Info: "Temozolomide (TMZ) is an alkylating chemotherapeutic agent primarily used in the treatment of glioblastoma multiforme, functioning by inhibiting DNA synthesis in cancer cells through methylation of guanine residues, and is often administered in combination with radiotherapy."
Effect: resist
Effect Info: "CGP57380 or cercosporamide, along with specific knockdown of MNK1, reduces the phosphorylation of eIF4E and enhances the sensitivity of glioblastoma (GBM) cells to TMZ."
Note:
Score: 5.0
Pubmed(PMID): 27289018
Sentence Index:
Sentence:

Sequence & Structure:

MATVEPETTPTPNPPTTEEEKTESNQEVANPEHYIKHPLQNRWALWFFKNDKSKTWQANLRLISKFDTVEDFWALYNHIQLSSNLMPGCDYSLFKDGIEPMWEDEKNKRGGRWLITLNKQQRRSDLDRFWLETLLCLIGESFDDYSDDVCGAVVNVRAKGDKIAIWTTECENREAVTHIGRVYKERLGLPPKIVIGYQSHADTATKSGSTTKNRFVV

Select PDB:

Known Drugs:

source: Multi-Sources

(see table)

No data.

Protein Tractability:

source: Open Targets
Small molecule
Antibody
PROTAC
Other modalities
Approved Drug
Advanced Clinical
Phase 1 Clinical
Structure with Ligand
High-Quality Ligand
High-Quality Pocket
Med-Quality Pocket
Druggable Family
Approved Drug
Advanced Clinical
Phase 1 Clinical
UniProt loc high conf
GO CC high conf
UniProt loc med conf
UniProt SigP or TMHMM
GO CC med conf
Human Protein Atlas loc
Approved Drug
Advanced Clinical
Phase 1 Clinical
Literature
UniProt Ubiquitination
Database Ubiquitination
Half-life Data
Small Molecule Binder
Approved Drug
Advanced Clinical
Phase 1 Clinical

PTM Intensity:

source: CPTAC

No intensity data of this site,
show all other sites!

EIF4E2-Ser13
Cancer Intensity
BRCA -1.17
COAD -1.099
HGSC 2.339
ccRCC 0.143
GBM -0.308
HNSC -0.364
LUAD -0.608
LUSC -0.163
non_ccRCC 1.13
PDAC -0.068
UCEC 0.168
EIF4EBP1-Ser101
Cancer Intensity
BRCA 0.104
COAD -0.799
HGSC -0.746
ccRCC -0.387
GBM 1.003
HNSC 0.086
LUAD 0.098
LUSC 0.282
non_ccRCC -2.103
PDAC 1.019
UCEC 1.442
EIF4EBP1-Ser35
Cancer Intensity
BRCA
COAD
HGSC -1.76
ccRCC 0.134
GBM
HNSC 0.587
LUAD 0.537
LUSC
non_ccRCC
PDAC
UCEC 0.502
EIF4EBP1-Ser44
Cancer Intensity
BRCA
COAD
HGSC -0.707
ccRCC
GBM
HNSC 0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC
EIF4EBP1-Ser65
Cancer Intensity
BRCA 0.635
COAD 0.808
HGSC 1.53
ccRCC -0.775
GBM 0.336
HNSC 0.064
LUAD -0.154
LUSC -0.134
non_ccRCC -2.413
PDAC 0.14
UCEC -0.038
EIF4EBP1-Ser83
Cancer Intensity
BRCA
COAD
HGSC -1.14
ccRCC
GBM -0.215
HNSC -0.224
LUAD -0.035
LUSC
non_ccRCC
PDAC
UCEC 1.613
EIF4EBP1-Ser85
Cancer Intensity
BRCA
COAD -0.46
HGSC -1.479
ccRCC 0.249
GBM
HNSC 1.079
LUAD 0.611
LUSC
non_ccRCC
PDAC
UCEC
EIF4EBP1-Ser86
Cancer Intensity
BRCA
COAD -0.459
HGSC -1.495
ccRCC 0.862
GBM
HNSC 0.874
LUAD 0.217
LUSC
non_ccRCC
PDAC
UCEC
EIF4EBP1-Ser94
Cancer Intensity
BRCA
COAD
HGSC -1.495
ccRCC 0.433
GBM
HNSC 0.449
LUAD 0.614
LUSC
non_ccRCC
PDAC
UCEC
EIF4EBP1-Ser96
Cancer Intensity
BRCA
COAD
HGSC -1.724
ccRCC 0.217
GBM
HNSC 0.175
LUAD 0.489
LUSC
non_ccRCC
PDAC
UCEC 0.843
EIF4EBP1-Thr36
Cancer Intensity
BRCA
COAD -0.003
HGSC -1.952
ccRCC 0.073
GBM
HNSC 0.576
LUAD 0.683
LUSC
non_ccRCC
PDAC
UCEC 0.622
EIF4EBP1-Thr37
Cancer Intensity
BRCA -0.074
COAD -0.449
HGSC -2.155
ccRCC -0.037
GBM
HNSC 0.413
LUAD 0.6
LUSC 0.56
non_ccRCC
PDAC
UCEC 1.142
EIF4EBP1-Thr45
Cancer Intensity
BRCA
COAD -0.144
HGSC -1.327
ccRCC
GBM
HNSC 0.473
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.998
EIF4EBP1-Thr46
Cancer Intensity
BRCA
COAD -0.052
HGSC -1.925
ccRCC
GBM
HNSC 0.653
LUAD 0.635
LUSC 0.007
non_ccRCC
PDAC
UCEC 0.681
EIF4EBP1-Thr68
Cancer Intensity
BRCA -1.086
COAD
HGSC 0.883
ccRCC
GBM
HNSC
LUAD 0.203
LUSC
non_ccRCC
PDAC
UCEC
EIF4EBP1-Thr70
Cancer Intensity
BRCA -0.163
COAD -0.958
HGSC 0.236
ccRCC 0.368
GBM 0.971
HNSC 0.887
LUAD 0.075
LUSC 0.183
non_ccRCC -2.352
PDAC
UCEC 0.753
EIF4EBP1-Thr77
Cancer Intensity
BRCA
COAD 1.075
HGSC 0.851
ccRCC -0.787
GBM -1.222
HNSC 0.082
LUAD
LUSC
non_ccRCC
PDAC
UCEC
EIF4EBP1-Thr82
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.707
GBM
HNSC 0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC
EIF4EBP1-Tyr34
Cancer Intensity
BRCA
COAD
HGSC -1.009
ccRCC
GBM
HNSC 0.991
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.018
EIF4EBP2-Ser44
Cancer Intensity
BRCA
COAD 0.192
HGSC
ccRCC 0.547
GBM 1.322
HNSC -0.259
LUAD -1.684
LUSC
non_ccRCC
PDAC
UCEC -0.118
EIF4EBP2-Ser65
Cancer Intensity
BRCA 2.116
COAD 0.783
HGSC -0.351
ccRCC 0.329
GBM 0.238
HNSC 0.733
LUAD -1.361
LUSC -0.944
non_ccRCC -1.112
PDAC -0.139
UCEC -0.293
EIF4EBP2-Thr36
Cancer Intensity
BRCA
COAD -1.215
HGSC
ccRCC -0.431
GBM
HNSC -0.37
LUAD 0.719
LUSC
non_ccRCC
PDAC
UCEC 1.297
EIF4EBP2-Thr37
Cancer Intensity
BRCA
COAD 0.42
HGSC -1.65
ccRCC 0.337
GBM
HNSC -0.096
LUAD 0.989
LUSC
non_ccRCC
PDAC
UCEC
EIF4EBP2-Thr41
Cancer Intensity
BRCA
COAD
HGSC -1.111
ccRCC
GBM
HNSC 0.828
LUAD 0.284
LUSC
non_ccRCC
PDAC
UCEC
EIF4EBP2-Thr45
Cancer Intensity
BRCA
COAD
HGSC 0.193
ccRCC 1.324
GBM
HNSC -0.588
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.929
EIF4EBP2-Thr46
Cancer Intensity
BRCA
COAD 0.147
HGSC -0.683
ccRCC -1.21
GBM 1.012
HNSC 1.19
LUAD 0.639
LUSC
non_ccRCC
PDAC
UCEC -1.095
EIF4EBP2-Thr70
Cancer Intensity
BRCA 2.325
COAD 0.445
HGSC 0.799
ccRCC -0.056
GBM 0.089
HNSC 0.34
LUAD -1.239
LUSC -0.812
non_ccRCC -1.019
PDAC -0.53
UCEC -0.341
EIF4EBP2-Thr82
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC 0.707
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.707
EIF4EBP2-Tyr34
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.06
GBM
HNSC 0.545
LUAD 0.59
LUSC
non_ccRCC
PDAC -1.715
UCEC 0.639
EIF4EBP3-Ser51
Cancer Intensity
BRCA
COAD 0.573
HGSC 1.751
ccRCC -0.767
GBM 1.034
HNSC 0.187
LUAD -0.534
LUSC -0.607
non_ccRCC -1.496
PDAC
UCEC -0.141
EIF4EBP3-Thr23
Cancer Intensity
BRCA 0.619
COAD 0.404
HGSC -2.534
ccRCC 0.219
GBM 0.481
HNSC
LUAD 0.507
LUSC 0.618
non_ccRCC 0.022
PDAC
UCEC -0.335
EIF4EBP3-Thr31
Cancer Intensity
BRCA
COAD 0.618
HGSC -1.154
ccRCC
GBM 0.536
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
EIF4EBP3-Thr32
Cancer Intensity
BRCA
COAD 0.818
HGSC -1.115
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.296
EIF4EBP3-Thr56
Cancer Intensity
BRCA
COAD 1.061
HGSC -1.885
ccRCC -0.426
GBM 1.332
HNSC 0.397
LUAD 0.433
LUSC -0.586
non_ccRCC -0.618
PDAC 0.937
UCEC -0.645
EIF4EBP3-Thr68
Cancer Intensity
BRCA
COAD 0.414
HGSC -1.837
ccRCC 0.028
GBM 0.939
HNSC 0.712
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.256
EIF4EBP3-Thr69
Cancer Intensity
BRCA
COAD 0.25
HGSC -1.737
ccRCC 0.158
GBM
HNSC 0.585
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.743
EIF4ENIF1-Ser115
Cancer Intensity
BRCA
COAD
HGSC 1.528
ccRCC
GBM 0.803
HNSC -0.721
LUAD
LUSC 0.114
non_ccRCC -0.867
PDAC
UCEC -0.858
EIF4ENIF1-Ser120
Cancer Intensity
BRCA
COAD
HGSC 1.178
ccRCC
GBM
HNSC 0.148
LUAD -0.066
LUSC -1.26
non_ccRCC
PDAC
UCEC
EIF4ENIF1-Ser136
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.707
GBM
HNSC
LUAD 0.707
LUSC
non_ccRCC
PDAC
UCEC
EIF4ENIF1-Ser138
Cancer Intensity
BRCA -1.244
COAD -0.054
HGSC 1.501
ccRCC -0.255
GBM -0.254
HNSC -0.369
LUAD -0.771
LUSC 0.006
non_ccRCC 2.231
PDAC -0.24
UCEC -0.552
EIF4ENIF1-Ser173
Cancer Intensity
BRCA 0.707
COAD -0.707
HGSC
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
EIF4ENIF1-Ser301
Cancer Intensity
BRCA -1.899
COAD 0.126
HGSC -1.968
ccRCC -0.152
GBM 0.586
HNSC 0.537
LUAD 0.881
LUSC 0.15
non_ccRCC 0.582
PDAC 0.731
UCEC 0.425
EIF4ENIF1-Ser342
Cancer Intensity
BRCA
COAD 0.939
HGSC
ccRCC
GBM -1.052
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC 0.113
EIF4ENIF1-Ser345
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
EIF4ENIF1-Ser351
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM 0.707
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.707
EIF4ENIF1-Ser352
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.203
HNSC
LUAD -0.883
LUSC
non_ccRCC
PDAC
UCEC 1.086
EIF4ENIF1-Ser353
Cancer Intensity
BRCA
COAD
HGSC 0.614
ccRCC 0.43
GBM -0.729
HNSC -1.32
LUAD -0.134
LUSC -0.03
non_ccRCC 1.272
PDAC -1.379
UCEC 1.275
EIF4ENIF1-Ser356
Cancer Intensity
BRCA -1.433
COAD
HGSC
ccRCC -0.922
GBM -0.077
HNSC
LUAD 0.54
LUSC 0.881
non_ccRCC
PDAC
UCEC 1.011
EIF4ENIF1-Ser374
Cancer Intensity
BRCA
COAD
HGSC 1.059
ccRCC
GBM 0.467
HNSC -0.127
LUAD -1.539
LUSC
non_ccRCC -1.123
PDAC 0.302
UCEC 0.961
EIF4ENIF1-Ser379
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC
LUAD -0.112
LUSC -0.447
non_ccRCC -0.868
PDAC 1.426
UCEC
EIF4ENIF1-Ser5
Cancer Intensity
BRCA 0.627
COAD 1.177
HGSC -2.192
ccRCC -0.016
GBM -0.701
HNSC 0.509
LUAD 0.563
LUSC 0.595
non_ccRCC 0.02
PDAC 0.664
UCEC -1.246
EIF4ENIF1-Ser513
Cancer Intensity
BRCA
COAD -0.263
HGSC 1.105
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC -0.842
UCEC
EIF4ENIF1-Ser564
Cancer Intensity
BRCA -0.031
COAD 0.337
HGSC 1.678
ccRCC -0.944
GBM 1.039
HNSC 0.43
LUAD 0.76
LUSC -0.225
non_ccRCC -1.907
PDAC -0.609
UCEC -0.529
EIF4ENIF1-Ser577
Cancer Intensity
BRCA -0.202
COAD 0.458
HGSC 2.19
ccRCC -0.14
GBM 0.516
HNSC -0.581
LUAD -0.045
LUSC 0.214
non_ccRCC -0.106
PDAC -0.255
UCEC -2.05
EIF4ENIF1-Ser587
Cancer Intensity
BRCA
COAD -0.506
HGSC -1.656
ccRCC -0.274
GBM 0.987
HNSC 0.428
LUAD -0.923
LUSC
non_ccRCC 1.59
PDAC 0.581
UCEC -0.227
EIF4ENIF1-Ser670
Cancer Intensity
BRCA -1.378
COAD -0.042
HGSC 1.578
ccRCC 0.266
GBM -0.418
HNSC -0.382
LUAD -0.307
LUSC -0.458
non_ccRCC 2.099
PDAC -0.319
UCEC -0.638
EIF4ENIF1-Ser680
Cancer Intensity
BRCA
COAD 1.305
HGSC
ccRCC -1.107
GBM
HNSC 0.061
LUAD -0.259
LUSC
non_ccRCC
PDAC
UCEC
EIF4ENIF1-Ser681
Cancer Intensity
BRCA
COAD 0.421
HGSC -1.786
ccRCC 0.415
GBM
HNSC 0.548
LUAD 0.402
LUSC
non_ccRCC
PDAC
UCEC
EIF4ENIF1-Ser69
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.059
GBM
HNSC 1.344
LUAD -0.215
LUSC
non_ccRCC
PDAC -1.07
UCEC
EIF4ENIF1-Ser690
Cancer Intensity
BRCA
COAD
HGSC
ccRCC -0.502
GBM
HNSC -0.484
LUAD -0.514
LUSC
non_ccRCC
PDAC
UCEC 1.5
EIF4ENIF1-Ser693
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM
HNSC 0.223
LUAD
LUSC
non_ccRCC
PDAC -1.093
UCEC 0.87
EIF4ENIF1-Ser74
Cancer Intensity
BRCA 1.123
COAD -0.228
HGSC -1.776
ccRCC
GBM 0.72
HNSC
LUAD 0.114
LUSC
non_ccRCC
PDAC
UCEC 0.046
EIF4ENIF1-Ser766
Cancer Intensity
BRCA
COAD
HGSC
ccRCC
GBM -0.116
HNSC
LUAD -0.937
LUSC
non_ccRCC
PDAC
UCEC 1.053
EIF4ENIF1-Ser768
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.234
GBM 0.862
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC -1.096
EIF4ENIF1-Ser77
Cancer Intensity
BRCA
COAD 0.057
HGSC -1.703
ccRCC
GBM -0.294
HNSC 0.316
LUAD 0.269
LUSC
non_ccRCC
PDAC
UCEC 1.355
EIF4ENIF1-Ser772
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
EIF4ENIF1-Ser78
Cancer Intensity
BRCA 0.148
COAD 0.28
HGSC -2.99
ccRCC 0.449
GBM 0.193
HNSC 0.332
LUAD 0.407
LUSC 0.129
non_ccRCC 0.554
PDAC 0.259
UCEC 0.238
EIF4ENIF1-Ser949
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 0.806
GBM -1.119
HNSC 0.313
LUAD
LUSC
non_ccRCC
PDAC
UCEC
EIF4ENIF1-Ser950
Cancer Intensity
BRCA
COAD
HGSC
ccRCC 1.066
GBM -0.713
HNSC 0.627
LUAD
LUSC
non_ccRCC
PDAC
UCEC -0.98
EIF4ENIF1-Ser951
Cancer Intensity
BRCA 0.042
COAD 0.533
HGSC -2.631
ccRCC 0.902
GBM -0.194
HNSC 0.248
LUAD 0.3
LUSC -0.542
non_ccRCC 1.128
PDAC 0.425
UCEC -0.211
EIF4ENIF1-Ser977
Cancer Intensity
BRCA 0.695
COAD
HGSC -2.369
ccRCC 0.302
GBM 0.571
HNSC
LUAD 0.053
LUSC -0.122
non_ccRCC -0.588
PDAC 0.905
UCEC 0.552
EIF4ENIF1-Thr215
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC
EIF4ENIF1-Thr357
Cancer Intensity
BRCA -1.295
COAD
HGSC -1.539
ccRCC 0.874
GBM 0.595
HNSC
LUAD 0.079
LUSC 0.642
non_ccRCC
PDAC
UCEC 0.646
EIF4ENIF1-Thr592
Cancer Intensity
BRCA -0.481
COAD
HGSC
ccRCC -0.801
GBM
HNSC 0.789
LUAD -0.578
LUSC 0.063
non_ccRCC 0.976
PDAC 1.467
UCEC -1.436
EIF4ENIF1-Thr769
Cancer Intensity
BRCA
COAD 0.707
HGSC -0.707
ccRCC
GBM
HNSC
LUAD
LUSC
non_ccRCC
PDAC
UCEC

PTM-Disease Association:

source: PTMD
Residue Position State Disease Class PMID
S 209 P Acute lymphoblastic leukemia Phosphorylation 23792164
S 209 P Prostate cancer/carcinoma/adenocarcinoma Phosphorylation 20679199
S 209 U Head and neck squamous cell carcinoma Phosphorylation 21281788
S 209 U Non-small cell squamous cell lung carcinoma Phosphorylation 20008839
S 209 U Psoriasis Phosphorylation 19663871
S 209 U Blast crisis chronic myeloid leukemia Phosphorylation 23737503
S 209 U Pathological scar Phosphorylation 23259313

State Note: Based on the distinct PTM states in diseases, PTMD classified all disease-associated PTMs into six classes, including whether the up-regulation (U) or down-regulation (D) of PTM levels, the absence (A) or presence (P) of PTMs, and the creation (C) or disruption (N) of PTM sites are associated with diseases.

PTM-Drug Perturbation Response:

source: DecryptM
Protein Gene PTM Position Modified sequence Cell Drug pEC50 Regulation Experiment
P06730 EIF4E P Ser209 SGS(ph)TTK A431 Dasatinib 6.4345 down
P06730 EIF4E P Ser209 SGS(ph)TTK A431 Gefitinib 9.2696 down
P06730 EIF4E P Ser209 SGS(ph)TTK A431 Afatinib 14.3791 -
P06730 EIF4E P Ser209 SGS(ph)TTK A431 Afatinib 5.2702 -
P06730 EIF4E P Ser209 SGS(ph)TTK A431 Afatinib 6.1583 -
P06730 EIF4E P Ser209 SGS(ph)TTK A431 Dasatinib 7.5981 -
P06730 EIF4E P Ser209 SGS(ph)TTK A431 Dasatinib 7.1189 -
P06730 EIF4E P Ser209 SGS(ph)TTK A431 Gefitinib 7.5922 -
P06730 EIF4E P Ser209 SGS(ph)TTK A431 Gefitinib 5.2991 -

pEC50 Note: pEC50 is the negative logarithm of EC50 (half-maximal effective concentration, dosage unit Mol), calculated as pEC50 = -log10(EC50), which quantifies the potency of a drug or compound.

Function score:

source: funscoR

No data.

Cross Links: